Product
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
1 clinical trial
10 indications
Indication
Bladder CancerIndication
MelanomaIndication
Head and Neck CancerIndication
Ovarian CancerIndication
Esophageal cancerIndication
Stomach CancerIndication
Synovial SarcomaIndication
Myxoid Round Cell LiposarcomaIndication
Gastroesophageal JunctionIndication
NSCLCClinical trial
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-27